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Abstract
Objectives. The effectiveness of inactivated influenza vaccine in people with autoimmune rheumatic disease
(AIRDs) is not known. We investigated whether the influenza vaccine is effective in preventing respiratory morbidity,
mortality and all-cause mortality in AIRD patients.
Methods. Adults with AIRDs treated with DMARDs prior to 1 September of each year between 2006 and 2009,
and 2010 and 2015 were identified from the Clinical Practice Research Datalink. Exposure and outcome data were
extracted. Data from multiple seasons were pooled. Propensity score (PS) for vaccination was calculated. Cox-
proportional hazard ratios (HRs) and 95% CIs were calculated, and were (i) adjusted, (ii) matched for PS for
vaccination.
Results. Data for 30 788 AIRD patients (65.7% female, 75.5% with RA, 61.1% prescribed MTX) contributing
125 034 influenza cycles were included. Vaccination reduced risk of influenza-like illness [adjusted HR (aHR) 0.70],
hospitalization for pneumonia (aHR 0.61) and chronic obstructive pulmonary disease exacerbations (aHR 0.67), and
death due to pneumonia (aHR 0.56) on PS-adjusted analysis in the influenza active periods (IAPs). The associations
were of similar magnitude and remained statistically significant on PS-matched analysis except for protection from
influenza-like illness, which became non-significant. Sub-analysis restricted to pre-IAP, IAP and post-IAP did not
yield evidence of residual confounding on influenza-like illness and death due to pneumonia. Vaccination reduced
risk of all-cause mortality, although IAP-restricted analysis demonstrated residual confounding for this outcome.
Conclusion. Influenza vaccine associates with reduced risk of respiratory morbidity and mortality in people with
AIRDs. These findings call for active promotion of seasonal influenza vaccination in immunosuppressed people with
AIRDs by healthcare professionals.
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Introduction
Influenza causes 291 000–650 000 deaths/year globally.
It is estimated to cause 3.1 million hospitalized days and
31.4 million outpatient visits, costing 87.1 billion dollars
to the USA economy annually [1, 2]. Inactivated influ-
enza vaccine (IIV) prevents influenza and its complica-
tions, with the degree of protection depending on
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vaccine match [3, 4]. According to the latest Cochrane
reviews, IIV prevents influenza and influenza-like illness
(ILI) in adults 65 years old (risk ratio 0.42 and 0.59, re-
spectively) and in young adults (risk ratio 0.41 and 0.84,
respectively) [3, 5]. It prevents chronic obstructive pul-
monary disease (COPD) exacerbation and lower respira-
tory tract infection (LRTI) in people with haematological
malignancy [6, 7]. However, its efficacy remains un-
proven in asthma, cystic fibrosis and in healthcare work-
ers for preventing influenza among care-home residents
[8–10]. Although observational studies report that IIV
prevents pneumonia, hospitalization and death, there is
a paucity of randomized controlled trial (RCT) evidence
for these outcomes [11–13].
Autoimmune rheumatic diseases (AIRDs) such as RA
and SpA associate with increased risk of influenza and
its complications, and seasonal flu vaccination is recom-
mended annually [14, 15]. While the magnitude of sero-
logical response to IIV has been examined in AIRDs, its
effectiveness in preventing patient-centred outcomes
such as influenza, pneumonia and death have not been
studied [16–18]. The only study to evaluate the effective-
ness of IIV in the context of immunosuppression had
<5% AIRD cases [11]. Moreover, there are concerns
that MTX, the first-choice DMARD, and rituximab impair
the serological response to IIV [16–18]. As lack of know-
ledge about the need for vaccination and vaccine effect-
iveness (VE) are barriers to vaccination, it is important to
examine whether IIV prevents respiratory morbidity and
mortality in AIRDs [19, 20]. Thus, the objectives of this
study were to assess the effectiveness of IIV in prevent-
ing ILI, LRTI, pneumonia, COPD exacerbations and
death in immunosuppressed AIRD patients.
Methods
Data source
Data from the Clinical Practice Research Datalink
(CPRD) were used. Incepted in 1987, CPRD is a longitu-
dinal anonymized electronic database containing health
records of >10 million people in the UK [21]. CPRD par-
ticipants are representative of the UK population in
terms of age, sex and ethnicity [21]. It contains details
of diagnoses stored as Read codes, a coded thesaurus
of clinical terms, primary care prescriptions and immuni-
zations. The data are enhanced by linkage with hospital-
ization (Hospital Episode Statistics) and mortality
records (Office of National Statistics). Data on prescrip-
tion of biologic agents prescribed by hospital-based
rheumatologists are not recorded. Ethical approval was
obtained from the Independent Scientific Advisory
Committe (ISAC) of the Medicines and Healthcare
Products Regulatory Agency, London (Ref: 16_288R).
Study design: cohort study
Population
One or more Read code for RA, lupus or SpA (defined
as either PsA, reactive arthritis, IBD-associated arthritis
or AS) in receipt of one or more prescription of immuno-
suppressive DMARDs (MTX, leflunomide, sulfasalazine,
AZA, ciclosporin, MMF or tacrolimus), registered in gen-
eral practitioner (GP) surgeries validated to meet CPRD
data standards, and 18 years in age. Participants only
ever prescribed the immunomodulatory drug HCQ were
excluded, as IIV is not recommended for HCQ prescrip-
tion in the UK [22].
Annual cohorts
The study period (1 September 2006 to 31August 2016)
was partitioned into influenza cycles of 12 months, be-
ginning on 1 September of one year and ending on 31
August of the subsequent year. Data for the 2009–10
cycle were excluded due to the use of monovalent
pandemic vaccine alongside trivalent IIV, and the
almost complete dominance of pandemic influenza
A(H1N1)pdm09 in the community.
To be included in a cohort for one influenza cycle,
participants had to be contributing data on the 1
September, with at least 3 months’ registration at their
current GP surgery, and receive a DMARD prescription
in this period. The 3 months prior registration period was
to allow the GP time to incorporate new patients into
local at-risk registers and to invite them for vaccination.
A subset of participants treated with long-term oral CS,
defined as two or more CS prescriptions in this 3-month
period was constructed for examining VE in those pre-
scribed DMARDs and CS.
Exposure
IIV administration was the exposure of interest.
Vaccination and date of vaccination were ascertained
using Read codes and event date [23] (supplementary
Table S1, available at Rheumatology online). An individ-
ual was defined as exposed (fully immunized) 14 days
after vaccination, in keeping with the typical time taken
for mounting a serological response to the IIV [22].
Influenza cycles in which the IIV was recorded in the
CPRD as being administered elsewhere, e.g. at work or
in community pharmacies, were excluded, as the exact
date of vaccination is not available in the CPRD.
Outcomes
We included a range of serious, e.g. hospitalization and
death, and less-serious outcomes, e.g. primary care
consultation for respiratory infections.
Primary care consultation for LRTI was defined as
diagnostic Read code for LRTI and antibiotic prescrip-
tion on the same date without preceding antibiotic pre-
scriptions or Read codes for LRTI within 21 days prior to
the eligible LRTI diagnosis date. Published Read code
lists were supplemented with additional codes as
required (supplementary Table S1, available at
Rheumatology online) [24].
Primary care consultation for ILI was defined as above
using published Read codes supplemented with add-
itional codes as above (supplementary Table S1, avail-
able at Rheumatology online) [25].
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Primary care consultation for COPD exacerbation was
defined as either Read code for acute COPD exacerba-
tion, or oral prednisolone and oral antibiotic prescrip-
tions occurring on the same date, with oral prednisolone
not prescribed as maintenance treatment in people with
COPD [24, 26]. Oral prednisolone was considered as
maintenance if two or more prescriptions were issued
within the previous 60 days.
Hospital admissions for pneumonia or COPD exacer-
bation were defined using International Classification of
Diseases-10 codes in the inpatient Hospital Episode
Statistics dataset.
Death including causes was defined using International
Classification of Diseases-10 codes in the Office of
National Statistics dataset.
Follow-up
In each of the influenza cycles, participants were
followed-up from 1 September until the earliest of out-
come date, date of death, date of last data collection,
transfer out of the GP-surgery or 31 August of the fol-
lowing year. A participant was defined as having an out-
come of interest on the date of first allocation of Read
code or International Classification of Diseases-10 code
in an influenza cycle.
IIV is most likely to have an effect on outcomes during
periods of influenza virus circulation, and the proportion
of ILI and other outcomes attributable to influenza virus
activity is greatest. Therefore, we undertook additional
analyses, restricting the outcomes to the influenza active
period (IAP).
Propensity score
As participants at risk of influenza are more likely to be
vaccinated, a propensity score (PS) for vaccination was
calculated [12]. The PS included factors that account for
confounding by indication [age, sex, socioeconomic sta-
tus, smoking status (a dummy category was created for
missing smoking data), at-risk conditions (i.e. chronic re-
spiratory, heart, kidney or neurological disease, immuno-
suppression or diabetes), Charlson comorbidity index],
and health-seeking behaviour (previous pneumococcal
and influenza vaccination, and number of primary care
consultations, number of prescribed drugs and number
of hospital admissions in the 12 months prior to the 1
September of each year) [12]. A separate PS was calcu-
lated for each influenza cycle for every participant using
logistic regression, treating vaccination status as the de-
pendent variable.
Statistical analyses
Data for all influenza cycles from every participant were
included in a single dataset. Mean, (S.D.), n (%) and
standardized difference (d) were used to examine cova-
riate balance between exposed and unexposed. Cox re-
gression was used to calculate hazard ratios (HRs) and
95% CIs with vaccination as exposure of interest,
adjusted for calendar year, and included participant
identifier as a clustering term to account for within-
person correlation. Adjusted vaccine effectiveness (aVE)
was calculated as (1 – adjusted HR)  100. Different
analyses were performed to evaluate the consistency of
results across different methods of accounting for pro-
pensity for vaccination as follows.
PS-adjusted
Vaccination was a time-varying exposure, i.e. the time
period from day-14 post-vaccination up to end of the in-
fluenza cycle was defined as exposed, whilst the period
before this was classed as unexposed. Participants
without a vaccination record in the influenza cycle were
considered unexposed for the entire duration. PS distri-
bution in the vaccinated and unvaccinated groups was
plotted on a histogram (supplementary Fig. S1, available
at Rheumatology online). To remove unexpected treat-
ment effects, influenza cycles in which there was no
vaccination in the highest decile of PS for vaccination,
and vaccination in the lowest decile of PS for vaccin-
ation were excluded [27]. Sensitivity and subgroup anal-
yses were performed, restricted to people with RA,
excluding influenza cycles with mild immunosuppressive
SSZ prescription alone, stratifying by age, and restrict-
ing the analysis to those additionally prescribed CS.
Inverse-probability of treatment weighing (IPTW) using
the PS was performed as an additional post hoc sensi-
tivity analysis because covariate adjustment using PS
potentially biases the estimation of marginal and condi-
tional HRs in a time-to-event analysis [28].
PS-matched
A 1:1 matched cohort was constructed using greedy
nearest neighbour matching without replacement speci-
fying a maximum calliper width of 0.001. The unexposed
participants were allocated a pseudo-exposure date of
their matched exposed pair. Standardized difference (d)
was used to examine covariate balance between the
exposed and unexposed participants (see supplemen-
tary methods, available at Rheumatology online). Any
covariates for which there was imbalance, defined as
d> 0.10, were included as additional covariates in the
model [29]. Analyses for VE were stratified for pre-IAP,
IAP and post-IAP to assess residual confounding. IAPs
were defined as per Public Health England reports using
information about rates of consultation for ILI, and isola-
tion of the seasonal influenza virus from virological senti-
nel surveys. Data management and analysis were
performed in Stata v14, Stata Corp LLC, Texas, USA.
Results
Data for 30 788 participants, 65.66% female, 75.49%
with RA, contributing 125 034 influenza cycles (87 212
vaccinated) were included (supplementary Table S2,
available at Rheumatology online). During the follow-up
period, there were mean (S.D.) 3.78 (2.46) vaccinations
administered. A total of 15 355 participants (49.87%)
received all possible vaccination, whereas 8444 (27.43%)
missed more than one potential vaccination (supplemen-
tary Table S8, available at Rheumatology online). Some
2942 participants had COPD and contributed 9909
Effectiveness of inactivated influenza vaccine
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influenza cycles. There were 17 876 vaccinated influenza
cycles PS-matched 1:1 to unprotected influenza cycles.
The covariate imbalance between exposed and unex-
posed influenza cycles reduced following PS-matching
(Table 1).
PS-adjusted analysis
IIV reduced risk of hospitalization for pneumonia, COPD
exacerbation, all-cause mortality and death due to
pneumonia (Table 2). On restricting follow-up period to
IAPs, IIV reduced risk of primary care consultations for
ILI (Table 3). These associations remained significant on
trimming-tails (Tables 2 and 3).
PS-matched analysis
Charlson comorbidity index, diabetes, chronic heart
and renal diseases had d>0.10 between vaccinated
and unvaccinated influenza cycles, and were
included as additional covariates. The results of PS-
matched analyses were consistent with PS-adjusted
analyses, with the exception of a lack of statistically
significant protective effect on ILI during IAPs
(Tables 4 and 5).
There was negative association between vaccination
and all-cause mortality in pre-IAP and post-IAP, and be-
tween vaccination and hospitalization for pneumonia
and COPD exacerbations in post-IAP (Table 6).
Sensitivity analyses
IIV protected from hospitalization for pneumonia, COPD
exacerbation, and all-cause and pneumonia-related
mortality in people with RA; when influenza cycles
exposed to SSZ alone were excluded, and in the over
65s (supplementary Tables S3–S5, available at
Rheumatology online). IIV reduced the risk of hospital-
ization for pneumonia and death in influenza cycles pre-
ceded by CS prescriptions, while there was a trend for
reduction in hospitalization for COPD exacerbations
(supplementary Table S6, available at Rheumatology on-
line). The associations remained unchanged on IPTW
using PS (supplementary Table S7, available at
Rheumatology online).
Discussion
This study reports that IIV reduces the risk of ILI by
30%, hospitalization for pneumonia by 39%, hospitaliza-
tion for COPD exacerbations by 33% and death due to
pneumonia by 52% in immunosuppressed AIRD patients
during IAPs. Similar results were observed when follow-
up was extended to the entire influenza cycle, except
for absence of protective effect on ILI. This observation
provides validity to the findings as the protective effect
on ILI is not expected to extend beyond IAP. The pro-
tective effect of IIV was present when the analysis was
restricted to people with greater immune dysfunction,
e.g. diagnosed with RA, exposed to CS, prescribed po-
tent DMARDs and age >65 years. We also observed a
TABLE 1 Covariate balance before and after PS-matching
Entire cohort PS-matched sample
Vaccinated
(n5 87 212)
Unvaccinated
(n5 37 822)
da Vaccinated
(n5 17 876)
Unvaccinated
(n517 876)
da
Continuous covariates, mean (S.D.)
Age (years) 64.13 (12.76) 55.88 (13.64) 0.625 58.69 (13.39) 58.06 (13.92) 0.047
Charlson’s comorbidity index 1.34 (1.58) 0.75 (1.23) 0.415 1.16 (1.57) 0.92 (1.37) 0.162
Index of Multiple Deprivation 3.12 (1.42) 3.16 (1.41) 0.032 3.15 (1.41) 3.16 (1.41) 0.004
Number of prescriptionsb 3.01 (7.13) 2.81 (4.88) 0.034 2.95 (9.33) 2.83 (4.78) 0.015
Number of consultationsb 19.92 (12.35) 15.39 (10.91) 0.389 17.24 (11.81) 17.08 (11.37) 0.014
Number of hospitalizationsb 0.15 (0.62) 0.12 (0.57) 0.040 0.19 (0.72) 0.13 (0.57) 0.100
Categorical covariates, n (%)
Male 28 495 (32.67) 13 430 (35.51) 0.060 6559 (36.69) 5894 (32.97) 0.078
Home visit 709 (0.81) 186 (0.49) 0.030 180 (1.01) 95 (0.53) 0.055
Current smoking 13 300 (15.25) 8656 (22.89) 0.195 4018 (22.48) 3807 (21.30) 0.029
Previous influenza vaccination 77 419 (88.77) 8787 (23.23) 1.758 8608 (48.15) 8609 (48.16) 0.0002
Previous pneumococcal vaccination 62 998 (72.24) 9214 (24.36) 1.092 7520 (42.07) 7327 (40.99) 0.022
Diabetes 10 509 (12.05) 1805 (4.77) 0.265 1786 (9.99) 1197 (6.70) 0.119
Immunosuppression 921 (1.06) 305 (0.81) 0.026 241 (1.35) 150 (0.84) 0.049
Chronic kidney disease 12 854 (14.74) 2780 (7.35) 0.237 2276 (12.73) 1634 (9.14) 0.115
Chronic respiratory disease 19 121 (21.92) 5205 (13.76) 0.214 3430 (19.19) 2986 (16.70) 0.065
Chronic heart disease 8208 (9.41) 1292 (3.42) 0.246 1352 (7.56) 863 (4.83) 0.113
Asplenia 34 (0.04) 26 (0.07) 0.013 11 (0.06) 7 (0.04) 0.009
aStandardized difference. bIn previous 12 months. PS: propensity score.
Georgina Nakafero et al.
4 https://academic.oup.com/rheumatology
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/advance-article-abstract/doi/10.1093/rheum
atology/keaa078/5803181 by Periodicals D
epartm
ent , H
allw
ard Library, U
niversity of N
ottingham
 user on 17 M
arch 2020
TABLE 2 Influenza vaccine effectiveness in AIRDs using data from entire influenza cycle: propensity score-adjusted
analysis
Outcomes Vaccinated Event rate
(95% CI)/1000
person-years
Unadjusted
HR (95% CI)
Adjusted
HRa (95% CI)
Adjusted
HRb (95% CI)
Adjusted
VEc %
(95% CI)
Primary care con-
sultation for
LRTI requiring
antibiotics
No 78.02 (75.59, 80.53) 1.00 1.00 1.00 –
Yes 100.97 (98.53, 103.46) 1.41 (1.34, 1.49) 1.07 (1.01, 1.13) 1.04 (0.97, 1.11) 4 (11, 3)
Primary care con-
sultation for ILI
No 6.96 (6.27, 7.73) 1.00 1.00 1.00 –
Yes 7.09 (6.48, 7.75) 0.91 (0.78, 1.06) 0.91 (0.74, 1.12) 0.89 (0.70, 1.13) 11 (13, 30)
Primary care con-
sultation for
COPD
exacerbation
No 240.89 (222.47, 260.84) 1.00 1.00 1.00 
Yes 275.45 (262.09, 289.48) 1.09 (0.94, 1.27) 0.96 (0.83, 1.12) 0.93 (0.79, 1.10) 7 (21, 10)
Hospitalization for
pneumonia
No 17.03 (15.59, 18.60) 1.00 1.00 1.00 –
Yes 20.37 (18.98, 21.86) 1.29 (1.12, 1.48) 0.59 (0.51, 0.69) 0.69 (0.58, 0.83) 31 (17, 42)
Hospitalization for
COPD
exacerbation
No 109.42 (93.85, 127.58) 1.00 1.00 1.00 –
Yes 88.74 (79.46, 99.10) 0.78 (0.57, 1.05) 0.59 (0.44, 0.80) 0.65 (0.46, 0.93) 35 (7, 54)
All-cause death No 18.75 (17.59, 19.99) 1.00 1.00 1.00 –
Yes 21.77 (20.69, 22.91) 1.10 (1.00, 1.20) 0.52 (0.47, 0.59) 0.66 (0.57, 0.75) 34 (25, 43)
Deaths due to
pneumonia
No 5.33 (4.56, 6.24) 1.00 1.00 1.00 –
Yes 5.74 (5.03, 6.56) 1.08 (0.85, 1.35) 0.47 (0.35, 0.63) 0.67 (0.47, 0.96) 33 (53, 4)
aModel 1: adjusted for propensity score for IIV and year. bModel 2: adjusted for propensity score for IIV and year with PS
trimmed tails. cVE: vaccine effectiveness from Model 2. AIRD: autoimmune rheumatic disease; COPD: chronic obstructive
pulmonary disease; HR: hazard ratio; ILI: influenza-like illness; LRTI: lower respiratory tract infection. Significant results are
in bold.
TABLE 3 Influenza vaccine effectiveness in AIRDs restricted to influenza-active periods: propensity score-adjusted
analysis
Outcomes Vaccinated Event rate
(95% CI)/1000
person-years
Unadjusted
HR (95% CI)
Adjusted HRa
(95% CI)
Adjusted HRb
(95% CI)
Adjusted
VEc %
(95% CI)
Primary care con-
sultation for
LRTI requiring
antibiotics
No 86.17 (82.53, 89.96) 1.00 1.00 1.00 –
Yes 114.43 (111.30, 117.65) 1.38 (1.30, 1.46) 1.05 (0.98, 1.13) 1.04 (0.96, 1.13) 4 (13, 4)
Primary care con-
sultation for ILI
No 9.23 (8.12, 10.51) 1.00 1.00 1.00 –
Yes 7.99 (7.21, 8.85) 0.85 (0.72, 1.01) 0.75 (0.60, 0.95) 0.70 (0.54, 0.92) 30 (8, 46)
Primary care con-
sultation for
COPD
exacerbation
No 275.20 (244.47, 309.80) 1.00 1.00 1.00 –
Yes 271.62 (255.84, 288.37) 0.98 (0.83, 1.15) 0.89 (0.74, 1.06) 0.87 (0.72, 1.05) 13 (5, 28)
Hospitalization for
pneumonia
No 17.51 (15.46, 19.82) 1.00 1.00 1.00 –
Yes 22.15 (20.41, 24.04) 1.25 (1.07, 1.46) 0.54 (0.45, 0.64) 0.61 (0.50, 0.75) 39 (25, 50)
Hospitalization for
COPD
exacerbation
No 122.17 (96.97, 153.91) 1.00 1.00 1.00 –
Yes 98.52 (86.82, 111.81) 0.74 (0.53, 1.03) 0.58 (0.42, 0.82) 0.67 (0.46, 0.99) 33 (1, 54)
All-cause death No 21.82 (20.06, 23.74) 1.00 1.00 1.00 –
Yes 22.23 (20.91, 23.64) 1.02 (0.91, 1.13) 0.47 (0.41, 0.54) 0.56 (0.48, 0.65) 44 (35, 52)
Deaths due to
pneumonia
No 6.44 (5.13, 7.90) 1.00 1.00 1.00 –
Yes 6 (5.13, 7.02) 0.94 (0.72, 1.22) 0.37 (0.27, 0.51) 0.48 (0.33, 0.71) 52 (29, 67)
AIRD: autoimmune rheumatic disease; COPD: chronic obstructive pulmonary disease; HR: hazard ratio; ILI: influenza-like ill-
ness; LRTI: lower respiratory tract infection. Significant results are in bold aModel1: Adjusted for propensity score for IIV
and year. bModel2: Adjusted for propensity score for IIV and year with PS trimmed tails. cModel3: VE: Vaccine effective-
ness from Model 2.
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TABLE 4 Influenza vaccine effectiveness in AIRDs using data from entire influenza cycle: propensity score-matched
analysis
Outcomes Vaccinated Event rate
(95% CI)/1000
person-years
Model 1 HR
(95% CI)a
Model 2 HR
(95% CI)b
Adjusted VE %
(95% CI)b
Primary care consult-
ation for LRTI
requiring antibiotics
No 78.36 (73.40, 83.66) 1.00 1.00 –
Yes 92.41 (87.30, 97.82) 1.18 (1.08, 1.29) 1.11 (1.02, 1.22) 11 (2, 22)
Primary care consult-
ation for ILI
No 8.41 (6.92, 10.22) 1.00 1.00 –
Yes 8.05 (6.67, 9.71) 0.97 (0.74, 1.27) 0.91 (0.69, 1.22) 9 (22, 31)
Primary care consult-
ation for COPD
exacerbation
No 268.07 (224.64, 319.88) 1.00 1.00 –
Yes 275.42 (242.56, 312.73) 1.02 (0.82, 1.27) 1.03 (0.82, 1.29) 3 (29, 18)
Hospitalization for
pneumonia
No 25.44 (21.91, 29.54) 1.00 1.00 –
Yes 15.81 (13.21, 18.93) 0.62 (0.49, 0.78) 0.50 (0.39, 0.63) 50 (37, 61)
Hospitalization for
COPD exacerbation
No 154.37 (115.26, 206.75) 1.00 1.00 –
Yes 78.80 (58.44, 106.26) 0.50 (0.34, 0.75) 0.46 (0.31, 0.70) 54 (30, 69)
All-cause death No 32.22 (29.17, 35.59) 1.00 1.00 –
Yes 18.94 (16.76, 21.40) 0.59 (0.50, 0.69) 0.45 (0.38, 0.53) 55 (47, 62)
Deaths due to
pneumonia
No 9.10 (7.09, 11.67) 1.00 1.00 –
Yes 4.88 (3.54, 6.74) 0.54 (0.36, 0.81) 0.43 (0.29, 0.66) 57 (34, 71)
aAdjusted for year and including patient ID as a clustering term. bAs in Model 1, and additionally adjusted for age,
Charlson comorbidity index, diabetes, chronic heart disease and chronic kidney disease. AIRD: autoimmune rheumatic dis-
ease; COPD: chronic obstructive pulmonary disease; HR: hazard ratio; ILI: influenza-like illness; LRTI: lower respiratory
tract infection.
Significant results are in bold.
TABLE 5 Influenza vaccine effectiveness in AIRDs restricted to influenza-active periods: propensity score-matched
analysis
Outcomes Vaccinated Event rate
(95% CI)/1000
person-years
Model 1 HR
(95% CI)a
Model 2 HR
(95% CI) b
Adjusted VE
% (95% CI)b
Primary care con-
sultation for
LRTI requiring
antibiotics
No 89.45 (83.09, 96.31) 1 1 –
Yes 101.81 (95.38, 108.69) 1.14 (1.03, 1.26) 1.08 (0.98, 1.20) 8 (20, 2)
Primary care con-
sultation for ILI
No 10.61 (8.59, 13.11) 1 1 –
Yes 8.67 (6.95, 10.80) 0.83 (0.61, 1.12) 0.79 (0.57, 1.08) 21 (8, 43)
Primary care con-
sultation for
COPD
exacerbation
No 283.66 (232.23, 346.47) 1 1 –
Yes 273.01 (234.91, 317.30) 0.95 (0.74, 1.22) 0.97 (0.75, 1.25) 3 (25, 25)
Hospitalization for
pneumonia
No 27.95 (23.50, 33.23) 1 –
Yes 18.14 (14.79, 22.26) 0.64 (0.49, 0.84) 0.52 (0.39, 0.69) 48 (31, 61)
Hospitalization for
COPD
exacerbation
No 161.41 (114.75, 227.04) 1 1 –
Yes 85.03 (60.13, 120.23) 0.52 (0.32, 0.82) 0.50 (0.30, 0.78) 50 (22, 70)
All-cause death No 36.25 (32.34, 40.63) 1 1 –
Yes 18.80 (16.19, 21.83) 0.52 (0.43, 0.63) 0.41 (0.33, 0.50) 59 (50, 67)
Deaths due to
pneumonia
No 11.51 (9.00, 15.07) 1 1 –
Yes 5.11 (3.48, 7.50) 0.44 (0.28, 0.71) 0.37 (0.23, 0.59) 63 (41, 77)
aAdjusted for year and including patient ID as a clustering term. bAs in Model 1, and, additionally adjusted for age,
Charlson comorbidity index, diabetes, chronic heart and chronic kidney disease. AIRD: autoimmune rheumatic disease;
COPD: chronic obstructive pulmonary disease; HR: hazard ratio; ILI: influenza-like illness; LRTI: lower respiratory tract in-
fection.
Significant results are in bold.
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protective effect of vaccination on all-cause mortality.
However, this is likely to be due to residual confounding
as IIV associated with significantly reduced all-cause
mortality in the pre-IAP when protection is not expected.
Similarly, a negative association between vaccination
and hospitalization for pneumonia and COPD exacerba-
tions in the post-IAP raises the possibility that residual
confounding may be present for these outcomes as
well. This residual confounding could be due to several
reasons such as healthy user bias, and selective non-
prescribing to people with poor functional status and
short life-expectancy, e.g. due to terminal illness, or the
hospitalized [30].
We performed both PS-adjusted, IPTW and PS-
matched analyses. The findings of PS-matched analysis
were consistent with PS-adjusted and IPTW analysis,
except for a lack of protective effect on ILI in the IAPs.
However, this may be related to a >70% reduction in
sample-size on PS-matching.
This large population-based study provides data on
the effectiveness of IIV in AIRDs. A previous study only
included <5% AIRD cases [11], and a recent smaller
study reported 35% VE for hospitalization due to septi-
caemia, bacteraemia or viremia, and 38% VE for all-
cause mortality with IIV in people with RA [31].
Our estimate of VE against ILI is comparable to those
observed in healthy adults [3, 5]. VE is lower when ILI, a
non-specific outcome with considerable imprecision
around diagnosis, is the outcome rather than laboratory-
confirmed influenza. ILI includes infections due to influ-
enza and other respiratory viruses, and, as the IIV only
targets the influenza virus, VE is lower for ILI than for la-
boratory-confirmed influenza [3, 5]. For example, in an
RCT, the VE for laboratory-confirmed influenza was
50% (1997/8) and 86% (1998/9), but VE for ILI was only
10 and 33%, respectively [32]. ILI cases presenting to
GPs in the UK do not routinely undergo virological
investigations and data on laboratory-confirmed influ-
enza are not available. Observational studies report
greater VE for complications of influenza such as pneu-
monia (27–45%) and death (38–48%) than for ILI [11–
13]. Our estimates of VE for pneumonia and death are
of similar magnitude.
Primary care consultation for LRTI was selected as an
outcome because bacterial chest infection is a compli-
cation of influenza. However, there was no evidence for
protective effect on this outcome. This was unexpected,
as IIV associated negatively with hospitalization and
death due to pneumonia. It is possible that risk-averse
antibiotic prescription to immunosuppressed people in
primary care contributed. Similarly, our finding of no evi-
dence of VE in those aged <45 years could be due to
very few events in this age group. However, protective
effects of IIV in young adults have been demonstrated
[5].
Our study demonstrates that IIV is more effective in
AIRDs than in diabetes [33]. This may be due to the fact
that people with diabetes are at a high risk of influenza
and its complications due to underlying immune dys-
function [34, 35]. However, VE in our study was compar-
able to that in healthy adults >65 years in age [3, 13,
36], despite reports of reduced serological response to
IIV in the elderly [37].
The humoral and T cell responses to IIV are main-
tained in AIRD patients treated with MTX or anti-TNFa
agents; however, B cell depletion therapy results in
maintained T cell responses but lower humoral
responses, and reduces the serological response to
vaccination [16, 38, 39]. A recent RCT demonstrated
greater antibody titres when MTX was temporarily dis-
continued post-vaccination [40]. However, 74 and 100%
of patients in the intervention arm developed protective
titres to the H1N1 and H3N2 viruses [40]. Prior to this
study, there was no evidence that discontinuing MTX
would boost serological response to IIV, and patients in
the UK continue MTX post-vaccination. Thus, our find-
ings together with the results of previous studies sug-
gest that the serological response in immunosuppressed
AIRD patients appears sufficient to offer protection from
influenza and its complications.
In this study, 69.8% of influenza cycles were in receipt
of an IIV. This may be due to financial incentives
TABLE 6 Influenza vaccine effectiveness in pre-IAP, IAP and post-IAP: propensity score-matched analysis
Outcomes Adjusted HR (95% CI)a
Pre-IAP IAP Post-IAP
Primary care consultation for LRTI requiring antibiotics 1.24 (0.55, 2.81) 1.08 (0.98, 1.20) 1.19 (0.98, 1.44)
Primary care consultation for ILI 3.02 (0.32, 28.22) 0.79 (0.57, 1.08) 1.49 (0.71, 3.16)
Primary care consultation for COPD exacerbation 1.20 (0.29, 5) 0.97 (0.75, 1.25) 1.46 (0.89, 2.38)
Hospitalization for pneumonia 0.19 (0.02, 1.66) 0.52 (0.39, 0.69) 0.50 (0.30, 0.83)
Hospitalization for COPD exacerbation –/– 0.50 (0.30, 0.78) 0.51 (0.25, 1.05)
All cause death 0.11 (0.02, 0.57) 0.41 (0.33, 0.50) 0.67 (0.48, 0.93)
Deaths due to pneumonia –/– 0.37 (0.23, 0.59) 0.88 (0.33, 2.35)
aAdjusted for year, age, Charlson comorbidity index, diabetes, chronic heart disease and chronic kidney disease, and
including patient ID as a clustering term (Model 2). –/–: no outcomes; COPD: chronic obstructive pulmonary disease; HR:
hazard ratio; IAP: influenza active periods; ILI: influenza-like illness; LRTI: lower respiratory tract infection.
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provided by the government to GPs under the Quality
and Outcomes Framework to vaccinate people with
comorbidities, e.g. diabetes, asthma or the elderly.
AIRDs are not included in this list of comorbidities, al-
though GPs retain discretion on whom to vaccinate.
Consequently, only half of immunosuppressed people
with AIRDs younger than 65 years old receive the IIV,
often quite late in the course of the flu season [23].
The effectiveness of IIV varies according to the circu-
lating influenza strain [4]. Although we could not assess
VE by influenza strain, our results are encouraging. The
findings of this study, together with the results of our
previous study demonstrating the safety of IIV in people
with AIRDs, provides evidence to promote seasonal flu
vaccination in this population [41].
Ideally, vaccine efficacy should be assessed in RCTs,
and the challenges in assessing VE using observational
data are well known. Nevertheless, there are several
strengths of this study, which include a large nationally
representative sample, use of combination of diagnostic
and prescription codes, and inclusion of broad-
spectrum of AIRDs. Studies of VE are biased due to
confounding by indication and healthy user bias, but we
attempted to account for this using PS for vaccination,
and the results of IAP-restricted analysis suggest that
our findings are confounded for all-cause mortality, and
potentially also for hospitalization for pneumonia and
COPD exacerbation for which there was evidence of a
protective effect in the post-IAP. In this study, analyses
were undertaken in data from all nine influenza cycles
included in a single dataset. This a priori approach gave
a more powerful analysis and increased precision for
less common outcomes. Sensitivity and subgroup analy-
ses confirmed protective effects in presence of greater
immunosuppression. Finally, the results were consistent
across PS-adjusted, IPTW using PS, and PS-matched
analyses, providing internal validity.
However, this study has several limitations. We merged
data from multiple influenza cycles and provide a single
VE estimate for each outcome. However, we accounted
for within-person correlations, and report robust standard
errors. Penicillamine and gold were excluded from the
DMARD list, however they are rarely prescribed now-
adays. Vaccinations occurring outside the GP surgery
may not be recorded in the CPRD, resulting in misclassi-
fication of vaccinated cycles as unvaccinated. However,
this biases the results towards null rather than inflating
VE estimates given our findings. Additionally, as data on
prescription of biological agents are not recorded in the
CPRD, we were unable to assess their impact on VE.
However, a proportion of people included in the study
are expected to be treated with biologics. Similarly, ex-
clusion of the 2009–10 flu season implies that our results
cannot be generalized to pandemic influenza. Although
we controlled for confounding, unmeasured confounding
and healthy user bias could have inflated VE [30]. Finally,
VE estimates from observational studies do not equate to
vaccine efficacy at population level. This is due to covari-
ate imbalance in PS-adjusted analysis that cannot be
entirely accounted for by covariate adjustment, and the
fact that PS-matched analysis is restricted to a sample
that differs from the entire population. However, it is eth-
ically challenging to justify an RCT of vaccination in this
at-risk population.
In conclusion, IIV prevents respiratory morbidity and
mortality in immunosuppressed AIRD patients. Although
the VE estimates reported here may be overestimated for
hospitalization and mortality outcomes given the observa-
tional study design, people with AIRDs should be informed
of the benefits of vaccination and offered IIV annually.
Supplementary data
Supplementary data are available at Rheumatology online.
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